Acorah Software Products - Accounts Production 19.3.550 false true 30 November 2024 1 December 2023 false 1 December 2024 30 November 2025 30 November 2025 14505346 Mr J Aldous Mrs E L Aldous iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 14505346 2024-11-30 14505346 2025-11-30 14505346 2024-12-01 2025-11-30 14505346 frs-core:CurrentFinancialInstruments 2025-11-30 14505346 frs-core:ComputerEquipment 2025-11-30 14505346 frs-core:ComputerEquipment 2024-12-01 2025-11-30 14505346 frs-core:ComputerEquipment 2024-11-30 14505346 frs-core:ShareCapital 2025-11-30 14505346 frs-core:RetainedEarningsAccumulatedLosses 2025-11-30 14505346 frs-bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 14505346 frs-bus:FilletedAccounts 2024-12-01 2025-11-30 14505346 frs-bus:SmallEntities 2024-12-01 2025-11-30 14505346 frs-bus:AuditExempt-NoAccountantsReport 2024-12-01 2025-11-30 14505346 frs-bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 14505346 frs-core:DeferredTaxation 2024-12-01 2025-11-30 14505346 frs-core:DeferredTaxation 2024-11-30 14505346 frs-core:DeferredTaxation 2025-11-30 14505346 frs-bus:Director1 2024-12-01 2025-11-30 14505346 frs-bus:Director2 2024-12-01 2025-11-30 14505346 frs-countries:EnglandWales 2024-12-01 2025-11-30 14505346 2023-11-30 14505346 2024-11-30 14505346 2023-12-01 2024-11-30 14505346 frs-core:CurrentFinancialInstruments 2024-11-30 14505346 frs-core:ShareCapital 2024-11-30 14505346 frs-core:RetainedEarningsAccumulatedLosses 2024-11-30
Registered number: 14505346
Aldous Clinical Research Consultancy Limited
Unaudited Financial Statements
For The Year Ended 30 November 2025
Peter Jarman LLP
Aldous Clinical Research Consultancy Limited
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—4

Page 1
Aldous Clinical Research Consultancy Limited
Balance Sheet
As At 30 November 2025
Balance Sheet
Registered number: 14505346

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 281 |  | 375
|  |  | 281 |  | 375
CURRENT ASSETS
Stocks |  | 4,214 |  | 5,262 |
Debtors | 5 | 577 |  | 7,805 |
Cash at bank and in hand |  | 16,202 |  | 6,730 |
|  | 20,993 |  | 19,797 |
Creditors: Amounts Falling Due Within One Year | 6 | (27,881 ) |  | (21,590 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | (6,888 ) |  | (1,793 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | (6,607 ) |  | (1,418 )
PROVISIONS FOR LIABILITIES
Deferred Taxation |  |  | (60 ) |  | (80 )
NET LIABILITIES |  |  | (6,667 ) |  | (1,498 )
CAPITAL AND RESERVES
Called up share capital | 8 |  | 2 |  | 2
Profit and Loss Account |  |  | (6,669 ) |  | (1,500 )
SHAREHOLDERS' FUNDS |  |  | (6,667) |  | (1,498)

Page 1
Page 2
Aldous Clinical Research Consultancy Limited
Balance Sheet (continued)
As At 30 November 2025
For the year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Mr J Aldous Director
22/07/2026

The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Aldous Clinical Research Consultancy Limited
Notes to the Financial Statements
For The Year Ended 30 November 2025
Notes to the Financial Statements
1. General Information
Aldous Clinical Research Consultancy Limited is a private company, limited by shares, incorporated in England & Wales, registered number 14505346 . The registered office is St James' Hall, Mill Road, Lancing, West Sussex, BN15 0PT.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
2.3. Tangible Fixed Assets and Depreciation
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life

Computer Equipment | 25% on reducing balance

2.4. Stocks and Work in Progress
Work in progress is valued at the lower of cost and net realisable value.
Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.
2.5. Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred Tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements.
Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 2 (2024: 2)
2 2
Page 3
Page 4
Aldous Clinical Research Consultancy Limited
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2025
4. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 1 December 2024 | 500
As at 30 November 2025 | 500
Depreciation
As at 1 December 2024 | 125
Provided during the period | 94
As at 30 November 2025 | 219
Net Book Value
As at 30 November 2025 | 281
As at 1 December 2024 | 375

5. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Trade debtors | 525 |  | 7,800
Other debtors | 52 |  | 5
| 577 |  | 7,805

6. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Other creditors | 64 |  | 30
Taxation and social security | 27,817 |  | 21,560
| 27,881 |  | 21,590

7. Provisions for Liabilities

| Deferred Tax | Total
--- | --- | ---
| £ | £
As at 1 December 2024 | 80 | 80
Utilised | (20 ) | (20)
Balance at 30 November 2025 | 60 | 60

8. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 2 |  | 2

Page 4